Drug Profile
Research programme: immuno-oncology therapies - Evotec SE/Exscientia
Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Evotec AG; Exscientia
- Developer Evotec SE; Exscientia
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors; Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in Germany
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in United Kingdom
- 09 Apr 2021 Evotec and Exscientia forms a joint venture to develop A2a receptor antagonist